HomeAI · summaries
Storia in 2 fonti
Amgen’s DLL3-targeted Imdelltra scores overall survival win in first-line small cell lung cancer
In further validation of the DLL3 target pioneered by Amgen’s Imdelltra, the T-cell engager has delivered an overall survival win in first-line small cell lung cancer (SCLC). | While Amgen gave no numerical results from Imdelltra's latest overall survival win in first-line small cell lung cancer, R&D chief Jay Bradner said data suggest the DLL3 bispecific “will further revolutionize the standard for survival earlier in the treatment journey.”
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
Amgen’s DLL3-targeted Imdelltra scores overall survival win in first-line small cell lung cancer
In further validation of the DLL3 target pioneered by Amgen’s Imdelltra, the T-cell engager has delivered an overall survival win in first-line small cell lung cancer (SCLC). |…
- ·
endpoints.news
Amgen’s lung cancer treatment Imdelltra notches major new victory
Amgen's Imdelltra plus AstraZeneca's Imfinzi improves overall survival in extensive-stage small cell lung cancer in Phase 3.